Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study

ABSTRACT Aims/Introduction This study evaluated the safety and effectiveness of dulaglutide in patients with type 2 diabetes in the real‐world setting in Japan. Materials and Methods This prospective, observational post‐marketing surveillance study was conducted for 36 months (July 2016 to July 2021...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Cutaneous Immunology and Allergy 2023-02, Vol.14 (2), p.247-258
Hauptverfasser:	Chin, Rina, Nagaoka, Soshi, Nakasawa, Haru, Tanaka, Yoko, Inagaki, Nobuya
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Age groups Aged Body Weight Clinical medicine Clinical trials Confidence intervals Data entry Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes type 2 Dulaglutide East Asian People Factor analysis Gastrointestinal diseases Glucagon Glucagon‐like peptide‐1 receptor Glycated Hemoglobin Glycosylated hemoglobin Hemoglobin Humans Hypoglycemia Hypoglycemic Agents - therapeutic use Marketing Medical laboratories Medical research Medicine, Experimental Observational studies Original Pancreatitis Patients Pharmaceutical industry Population Prospective Studies Safety Safety and security measures Type 2 diabetes Vital signs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ABSTRACT Aims/Introduction This study evaluated the safety and effectiveness of dulaglutide in patients with type 2 diabetes in the real‐world setting in Japan. Materials and Methods This prospective, observational post‐marketing surveillance study was conducted for 36 months (July 2016 to July 2021) in Japan. Investigators reported data via an electronic data capture system. Data were analyzed by overall population and age group (
ISSN:	2040-1116 2040-1124
DOI:	10.1111/jdi.13932